259 related articles for article (PubMed ID: 33351916)
1. Multiple polymerase acidic (PA) I38X substitutions in influenza A(H1N1)pdm09 virus permit polymerase activity and cause reduced baloxavir inhibition.
Jones JC; Pascua PNQ; Harrington WN; Webby RJ; Govorkova EA
J Antimicrob Chemother; 2021 Mar; 76(4):957-960. PubMed ID: 33351916
[TBL] [Abstract][Full Text] [Related]
2. Rapid detection of an I38T amino acid substitution in influenza polymerase acidic subunit associated with reduced susceptibility to baloxavir marboxil.
Nakauchi M; Takashita E; Fujisaki S; Shirakura M; Ogawa R; Morita H; Miura H; Saito S; Watanabe S; Odagiri T; Kageyama T
Influenza Other Respir Viruses; 2020 Jul; 14(4):436-443. PubMed ID: 32064779
[TBL] [Abstract][Full Text] [Related]
3. Influenza A virus polymerase acidic protein E23G/K substitutions weaken key baloxavir drug-binding contacts with minimal impact on replication and transmission.
Jones JC; Zagribelnyy B; Pascua PNQ; Bezrukov DS; Barman S; Okda F; Webby RJ; Ivanenkov YA; Govorkova EA
PLoS Pathog; 2022 Jul; 18(7):e1010698. PubMed ID: 35830486
[TBL] [Abstract][Full Text] [Related]
4. Treatment-Emergent Influenza Virus Polymerase Acidic Substitutions Independent of Those at I38 Associated With Reduced Baloxavir Susceptibility and Virus Rebound in Trials of Baloxavir Marboxil.
Ince WL; Smith FB; O'Rear JJ; Thomson M
J Infect Dis; 2020 Aug; 222(6):957-961. PubMed ID: 32253432
[TBL] [Abstract][Full Text] [Related]
5. Influenza A and B viruses with reduced baloxavir susceptibility display attenuated in vitro fitness but retain ferret transmissibility.
Jones JC; Pascua PNQ; Fabrizio TP; Marathe BM; Seiler P; Barman S; Webby RJ; Webster RG; Govorkova EA
Proc Natl Acad Sci U S A; 2020 Apr; 117(15):8593-8601. PubMed ID: 32217734
[TBL] [Abstract][Full Text] [Related]
6. Impact of the Baloxavir-Resistant Polymerase Acid I38T Substitution on the Fitness of Contemporary Influenza A(H1N1)pdm09 and A(H3N2) Strains.
Checkmahomed L; M'hamdi Z; Carbonneau J; Venable MC; Baz M; Abed Y; Boivin G
J Infect Dis; 2020 Jan; 221(1):63-70. PubMed ID: 31419295
[TBL] [Abstract][Full Text] [Related]
7. Development of cycling probe based real-time PCR methodology for influenza A viruses possessing the PA/I38T amino acid substitution associated with reduced baloxavir susceptibility.
Osada H; Chon I; Phyu WW; Wagatsuma K; Nagata N; Kawashima T; Sato I; Saito T; Kodo N; Masaki H; Asoh N; Tsuchihashi Y; Shirahige Y; Ono Y; Shimada Y; Hamabata H; Saito K; Saito R
Antiviral Res; 2021 Apr; 188():105036. PubMed ID: 33577807
[TBL] [Abstract][Full Text] [Related]
8. Comprehensive assessment of amino acid substitutions in the trimeric RNA polymerase complex of influenza A virus detected in clinical trials of baloxavir marboxil.
Hashimoto T; Baba K; Inoue K; Okane M; Hata S; Shishido T; Naito A; Wildum S; Omoto S
Influenza Other Respir Viruses; 2021 May; 15(3):389-395. PubMed ID: 33099886
[TBL] [Abstract][Full Text] [Related]
9. Characterization of contemporary influenza B recombinant viruses harboring mutations of reduced susceptibility to baloxavir marboxil, in vitro and in mice.
Abed Y; Fage C; Checkmahomed L; Venable MC; Boivin G
Antiviral Res; 2020 Jul; 179():104807. PubMed ID: 32343991
[TBL] [Abstract][Full Text] [Related]
10. Pleiotropic Effects of Influenza H1, H3, and B Baloxavir-Resistant Substitutions on Replication, Sensitivity to Baloxavir, and Interferon Expression.
Hickerson BT; Adams SE; Barman S; Miller L; Lugovtsev VY; Webby RJ; Ince WL; Donnelly RP; Ilyushina NA
Antimicrob Agents Chemother; 2022 Apr; 66(4):e0000922. PubMed ID: 35262375
[TBL] [Abstract][Full Text] [Related]
11. Impact of Baloxavir Resistance-Associated Substitutions on Influenza Virus Growth and Drug Susceptibility.
Hickerson BT; Petrovskaya SN; Dickensheets H; Donnelly RP; Ince WL; Ilyushina NA
J Virol; 2023 Jul; 97(7):e0015423. PubMed ID: 37404185
[TBL] [Abstract][Full Text] [Related]
12. Effect of Baloxavir and Oseltamivir in Combination on Infection with Influenza Viruses with PA/I38T or PA/E23K Substitutions in the Ferret Model.
Koszalka P; George A; Dhanasekaran V; Hurt AC; Subbarao K
mBio; 2022 Aug; 13(4):e0105622. PubMed ID: 35938724
[TBL] [Abstract][Full Text] [Related]
13. A rapid pyrosequencing assay for the molecular detection of influenza viruses with reduced baloxavir susceptibility due to PA/I38X amino acid substitutions.
Koszalka P; Farrukee R; Mifsud E; Vijaykrishna D; Hurt AC
Influenza Other Respir Viruses; 2020 Jul; 14(4):460-464. PubMed ID: 32045100
[TBL] [Abstract][Full Text] [Related]
14. Global update on the susceptibilities of human influenza viruses to neuraminidase inhibitors and the cap-dependent endonuclease inhibitor baloxavir, 2017-2018.
Takashita E; Daniels RS; Fujisaki S; Gregory V; Gubareva LV; Huang W; Hurt AC; Lackenby A; Nguyen HT; Pereyaslov D; Roe M; Samaan M; Subbarao K; Tse H; Wang D; Yen HL; Zhang W; Meijer A
Antiviral Res; 2020 Mar; 175():104718. PubMed ID: 32004620
[TBL] [Abstract][Full Text] [Related]
15. Global update on the susceptibilities of human influenza viruses to neuraminidase inhibitors and the cap-dependent endonuclease inhibitor baloxavir, 2018-2020.
Govorkova EA; Takashita E; Daniels RS; Fujisaki S; Presser LD; Patel MC; Huang W; Lackenby A; Nguyen HT; Pereyaslov D; Rattigan A; Brown SK; Samaan M; Subbarao K; Wong S; Wang D; Webby RJ; Yen HL; Zhang W; Meijer A; Gubareva LV
Antiviral Res; 2022 Apr; 200():105281. PubMed ID: 35292289
[TBL] [Abstract][Full Text] [Related]
16. Influenza A(H1N1)pdm09 virus exhibiting reduced susceptibility to baloxavir due to a PA E23K substitution detected from a child without baloxavir treatment.
Takashita E; Abe T; Morita H; Nagata S; Fujisaki S; Miura H; Shirakura M; Kishida N; Nakamura K; Kuwahara T; Mitamura K; Ichikawa M; Yamazaki M; Watanabe S; Hasegawa H;
Antiviral Res; 2020 Aug; 180():104828. PubMed ID: 32574689
[TBL] [Abstract][Full Text] [Related]
17. Treatment-Emergent Influenza Variant Viruses With Reduced Baloxavir Susceptibility: Impact on Clinical and Virologic Outcomes in Uncomplicated Influenza.
Uehara T; Hayden FG; Kawaguchi K; Omoto S; Hurt AC; De Jong MD; Hirotsu N; Sugaya N; Lee N; Baba K; Shishido T; Tsuchiya K; Portsmouth S; Kida H
J Infect Dis; 2020 Jan; 221(3):346-355. PubMed ID: 31309975
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetic and pharmacodynamic analysis of baloxavir marboxil, a novel cap-dependent endonuclease inhibitor, in a murine model of influenza virus infection.
Ando Y; Noshi T; Sato K; Ishibashi T; Yoshida Y; Hasegawa T; Onishi M; Kitano M; Oka R; Kawai M; Yoshida R; Sato A; Shishido T; Naito A
J Antimicrob Chemother; 2021 Jan; 76(1):189-198. PubMed ID: 33035324
[TBL] [Abstract][Full Text] [Related]
19. Duration of fever and PA/I38X-substituted virus emergence in patients treated with baloxavir in the 2018-2019 influenza season.
Ikematsu H; Kawai N; Tani N; Chong Y; Iwaki N; Bando T; Tanaka O; Matsuura S; Maeda T; Doniwa K
J Infect Chemother; 2020 Apr; 26(4):400-402. PubMed ID: 31870588
[TBL] [Abstract][Full Text] [Related]
20. Baloxavir-oseltamivir combination therapy inhibits the emergence of resistant substitutions in influenza A virus PA gene in a mouse model.
Park JH; Kim B; Antigua KJC; Jeong JH; Kim CI; Choi WS; Oh S; Kim CH; Kim EG; Choi YK; Baek YH; Song MS
Antiviral Res; 2021 Sep; 193():105126. PubMed ID: 34217753
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
